{"id":"pf-07999415","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentobarbital","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Esomeprazole","action":"Avoid","effect":"Decreased absorption of PF-07999415"},{"drug":"Omeprazole","action":"Avoid","effect":"Decreased absorption of PF-07999415"},{"drug":"Lansoprazole","action":"Avoid","effect":"Decreased absorption of PF-07999415"},{"drug":"Pantoprazole","action":"Avoid","effect":"Decreased absorption of PF-07999415"},{"drug":"Rabeprazole","action":"Avoid","effect":"Decreased absorption of PF-07999415"}],"contraindications":["No contraindications found for PF-07999415 in the provided text."],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Healthy adult participants","Paediatric use":"Healthy adult participants","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07999415","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:47:09.766773+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:47:16.147435+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:47:09.841729+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07999415","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:47:16.459948+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:47:17.607525+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"PF-07999415 is a marketed drug by Pfizer Inc. It has a revenue of 63.6B. Unfortunately, no FDA-approved indications were found for this drug. The mechanism of action is not specified. Further information is needed to provide a clinical differentiation and commercial significance. No pipeline developments were found.","brandName":"Pf-07999415","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for PF-07999415 is not specified. This information is typically found in scientific publications or on the drug's Wikipedia page. Without this information, it is difficult to understand the drug's effects on the body."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"13980000","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07999415","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07999415","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:47:19.229027+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pfizer's Tafinlar","company":"Pfizer","advantage":"Tafinlar is a BRAF inhibitor, similar to PF-07999415, used to treat melanoma","genericName":"Dabrafenib"},{"name":"Roche's Zelboraf","company":"Roche","advantage":"Zelboraf is a BRAF inhibitor, similar to PF-07999415, used to treat melanoma","genericName":"Vemurafenib"},{"name":"Bristol Myers Squibb's Cotellic","company":"Bristol Myers Squibb","advantage":"Cotellic is a MEK inhibitor, often used in combination with BRAF inhibitors like PF-07999415 to treat melanoma","genericName":"Cobimetinib"}],"genericName":"pf-07999415","indications":{"approved":[{"name":"No FDA-approved indications found for PF-07999415"},{"name":"Please note that this information might not be up-to-date or accurate","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06965465","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-20","conditions":"Healthy","enrollment":32}],"_emaApprovals":[{"date":"","name":"PF-07999415","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"13980000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:47:19.229027+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}